| Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials B Carlisle, J Kimmelman, T Ramsay, N MacKinnon Clinical trials 12 (1), 77-83, 2015 | 255 | 2015 |
| Benefit, risk, and outcomes in drug development: a systematic review of sunitinib B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ... JNCI: Journal of the National Cancer Institute 108 (1), 2016 | 59 | 2016 |
| Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review J Mattina, B Carlisle, Y Hachem, D Fergusson, J Kimmelman PLoS biology 15 (2), e2000487, 2017 | 40 | 2017 |
| Rethinking Research Ethics: The Case of Postmarketing Trials AJ London, J Kimmelman, B Carlisle Science 336 (6081), 544-545, 2012 | 40 | 2012 |
| Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials A Hakala, J Kimmelman, B Carlisle, G Freeman, D Fergusson BMJ 350, 2015 | 33 | 2015 |
| Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval B Carlisle, CA Federico, J Kimmelman Bmj 360, 2018 | 18 | 2018 |
| Drug development at the portfolio level is important for policy, care decisions and human protections J Kimmelman, B Carlisle, M Gönen Jama 318 (11), 1003-1004, 2017 | 14 | 2017 |
| Proof of prespecified endpoints in medical research with the bitcoin blockchain BG Carlisle The Grey Literature 25, 2014 | 14 | 2014 |
| Imatinib and the long tail of targeted drug development BG Carlisle, T Zheng, J Kimmelman Nature Reviews Clinical Oncology 17 (1), 1-3, 2020 | 11 | 2020 |
| Clinical trials stopped by Covid-19 BG Carlisle Open Science, 2020 | 8 | 2020 |
| Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs CA Federico, B Carlisle, J Kimmelman, DA Fergusson British journal of pharmacology 171 (18), 4247-4254, 2014 | 7 | 2014 |
| Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study BG Carlisle, A Doussau, J Kimmelman BMJ open 10 (2), e034306, 2020 | 5 | 2020 |
| Numbat meta-analysis extraction manager BG Carlisle | 5 | 2017 |
| Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers M Salholz-Hillel, D Strech, BG Carlisle Clinical Trials 19 (3), 337-346, 2022 | 4 | 2022 |
| Patient participation in clinical trials of oncology drugs and biologics preceding approval by the US Food and Drug Administration N Hutchinson, B Carlisle, A Doussau, R Bosan, E Gumnit, A MacPherson, ... JAMA network open 4 (5), e2110456-e2110456, 2021 | 4 | 2021 |
| Impact of precision medicine on efficiencies of novel drug development in cancer H Sarvas, B Carlisle, S Dolter, E Vinarov, J Kimmelman JNCI: Journal of the National Cancer Institute 112 (8), 859-862, 2020 | 4 | 2020 |
| Benefit, burden, and impact for a cohort of post-approval cancer combination trials BG Carlisle, A Doussau, J Kimmelman Clinical Trials 17 (1), 18-29, 2020 | 4 | 2020 |
| Analysis of clinical trial registry entry histories using the novel R package cthist BG Carlisle Plos one 17 (7), e0270909, 2022 | 3 | 2022 |
| How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials. gov N Hutchinson, K Klas, BG Carlisle, J Kimmelman, M Waligora Plos one 17 (1), e0262114, 2022 | 3 | 2022 |
| How well are phase 2 cancer trial publications supported by preclinical efficacy evidence? M Pratte, S Ganeshamoorthy, B Carlisle, J Kimmelman International Journal of Cancer 145 (12), 3370-3375, 2019 | 3 | 2019 |
Jonathan KimmelmanBiomedical Ethics, McGill UniversityVerified email at mcgill.ca
